PwC's Glenn Hunzinger stops by to discuss the  <a href="https://protect-us.mimecast.com/s/OT4zClYvpnu16jkOlsLCv0B?domain=nam12.safelinks.protection.outlook.com" rel="noopener noreferrer" target="_blank">Pharmaceutical and life sciences deals insights: 2021 midyear outlook report</a>, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.

PwC's Glenn Hunzinger stops by to discuss the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.

PwC's Glenn Hunzinger stops by to discuss the &nbsp;<a href="https://protect-us.mimecast.com/s/OT4zClYvpnu16jkOlsLCv0B?domain=nam12.safelinks.protection.outlook.com" rel="noopener noreferrer">Pharmaceutical and life sciences deals insights: 2021 midyear outlook report</a>, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.

Let's Talk Medtech with PwC's Glenn Hunzinger

MD+DI editors discuss current trends in the medical device and diagnostics industry, and point out developments to watch in the coming months.

Share Let's Talk Medtech with PwC's Glenn Hunzinger

Sign up to save your podcasts

Let's Talk Medtech with PwC's Glenn Hunzinger

Let's Talk Medtech with PwC's Glenn Hunzinger

More shows like Let’s Talk Medtech

The Daily